Hao-Yuan Chuang, Chief Financial Officer and Director of Belite Bio, Inc, filed a Form 4 on October 30, 2026, disclosing the vesting of 5,000 ordinary shares from a restricted stock unit award originally granted on September 15, 2025.

Key Highlights

  • RSU vesting: 5,000 ordinary shares vested on October 29, 2026, following satisfaction of certain performance criteria tied to an RSU award granted September 15, 2025.
  • Zero-cost acquisition: The shares were acquired at a price of $0, according to the filing.
  • Direct ownership after transaction: Chuang directly beneficially owned 180,264 ordinary shares following the reported transaction.
  • Indirect ownership: An additional 30,000 ordinary shares are held indirectly through ESHJ Ltd, a company the filing states is wholly beneficially owned by the reporting person.
  • Prior transfer noted: The 30,000 shares held by ESHJ Ltd were transferred to that entity on June 8, 2026, from direct ownership previously reported.
  • Transaction code: The transaction was coded "J," indicating a transaction not reportable under another code.

RSU Performance Criteria Met, Triggering Chuang's Share Vesting at Belite Bio

According to the Form 4 filed with the SEC, Hao-Yuan Chuang, who serves as both Chief Financial Officer and Director of Belite Bio, Inc (NASDAQ:BLTE), acquired 5,000 ordinary shares on October 29, 2026, through the vesting of restricted stock units. The filing explains that the RSUs were originally granted on September 15, 2025, and were structured to vest "upon satisfaction of several performance criteria." The filing states that certain of those criteria were met on October 29, 2026, triggering the vesting as to 5,000 ordinary shares at a price of $0.

Following the transaction, the filing reports Chuang directly beneficially owned 180,264 ordinary shares. The filing also notes that 30,000 ordinary shares are held indirectly through ESHJ Ltd. The filing explains that these 30,000 shares, previously reported as directly owned, were transferred by Chuang to ESHJ Ltd on June 8, 2026, and that ESHJ Ltd is a company wholly beneficially owned by the reporting person. The direct ownership figure of 180,264 shares excludes those 30,000 indirectly held shares, as stated in the filing's footnotes.

The Form 4 was signed by Hao-Yuan Chuang and filed on October 30, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Belite Bio CFO and Director Hao-Yuan Chuang disclosed the performance-based vesting of 5,000 ordinary shares on October 29, 2026, from an RSU grant dated September 15, 2025, with a resulting direct beneficial ownership of 180,264 ordinary shares and indirect ownership of 30,000 shares through ESHJ Ltd.